SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. , a biopharmaceutical research and development company focused on commercializing anticancer and antiviral therapies, announced today that Evan M. Levine, Chief Executive Officer, will present a corporate overview at the 9th Annual BIO CEO & Investor Conference on February 12th at 12:30pm EST. BIO CEO takes place in New York City at The Waldorf Astoria Hotel, February 12-14, 2007.
The BIO CEO conference is hosted by the Biotechnology Industry Organization (BIO), an organization focused exclusively on biotechnology. Attendees will include institutional investors, industry analysts, venture capitalists, investment bankers and other industry experts. Additional conference details and online registration are available at www.bio.org.
A live web cast of the presentation will be available and can be accessed via the “Investors” section of the Company’s corporate web site at http://www.adventrx.com under “Events.” After the live web cast, the presentation will remain available on the Company’s web site for 14 days.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing anticancer and antiviral therapies that improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. The Company’s lead product candidate, CoFactor (ANX-510), is currently being tested in a pivotal Phase III study for metastatic colorectal cancer in the US. More information can be found on the Company’s corporate web site at http://www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual results to differ materially include, but are not limited to: uncertainties inherent in the drug development process; the timing and success of clinical trials; the validity of research results; the receipt of necessary approvals from the FDA and other regulatory agencies; and other risks and uncertainties more fully described in ADVENTRX’s press releases and public filings with the Securities and Exchange Commission. ADVENTRX’s public filings with the Securities and Exchange Commission are available at www.sec.gov. ADVENTRX does not intend to update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made.
ADVENTRX Pharmaceuticals, Inc.
CONTACT: Investors, Ioana C. Hone of ADVENTRX Pharmaceuticals, Inc.,+1-858-552-0866; or Media, Amy Martini of WeissComm Partners,+1-212-301-7223, for ADVENTRX Pharmaceuticals, Inc.
Web site: http://www.adventrx.com/
Company News On-Call: http://www.prnewswire.com/gh/cnoc/comp/920134.html/
